 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Abatacept for People with Active Rheumatoid Arthritis
20 June 2006 | Volume 144 Issue 12 | Page I-18
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. A Randomized Trial." It is in the 20 June 2006 issue of Annals of Internal Medicine (volume 144, pages 865-876). The authors are J.M. Kremer, H.K. Genant, L.W. Moreland, A.S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, T. Li, Z. Ge, J.-C. Becker, and R. Westhovens.
What is the problem and what is known about it so far?
Rheumatoid arthritis is joint pain and stiffness caused by an immune reaction to joint tissue linings. It damages the joints and can even destroy them. Rheumatoid arthritis usually affects the hands, feet, knees, shoulders, and wrists, but it can develop in any joint. There is no cure, but treatment improves signs and symptoms and slows joint damage. Treatment is with drugs that alter the body's immune reactions. Abatacept is a new drug that targets specific components of the immune system. Abatacept inhibits the specific immune cells that cause rheumatoid arthritis and has been shown to improve symptoms in people with rheumatoid arthritis. It has not been directly compared with drugs that are commonly used to treat rheumatoid arthritis, such as methotrexate.
Why did the researchers do this particular study?
To compare the ability of abatacept and methotrexate to improve symptoms and slow joint damage in people with rheumatoid arthritis.
Who was studied?
652 adults with painful rheumatoid arthritis despite taking methotrexate for at least 3 months.
How was the study done?
The researchers assessed participants' symptoms and signs, ability to perform everyday activities, and quality of life before starting the study. They also looked at disease activity by measuring joint damage in x-rays. The researchers then randomly assigned participants to receive abatacept or placebo for 1 year. Abatacept was given intravenously twice in the first month, then once a month for 11 more months. Participants in both groups continued taking methotrexate. The researchers repeated their measurements every month to assess improvement.
What did the researchers find?
Participants taking abatacept improved more in all measures than participants taking placebo. Their symptoms and signs, everyday activities, and quality of life improved. Joint damage also progressed at half the rate. Participants in the 2 groups experienced similar adverse events. More participants taking abatacept experienced side effects, and they tended to develop infections more often. However, more participants taking placebo left the study prematurely because their symptoms and signs of rheumatoid arthritis did not improve.
What were the limitations of the study?
The study included participants who had had rheumatoid arthritis for more than a year and whose condition had not improved with methotrexate treatment. The findings may not apply to people with newer disease or to those who responded to methotrexate. The study lasted only a year. The benefits and risks of abatacept for longer periods require study.
What are the implications of the study?
Abatacept seems to be safe and effective for people with rheumatoid arthritis who do not respond to methotrexate treatment. The benefits and risks of taking abatacept for more than a year require more study. The role of the drug for different people at different stages of rheumatoid arthritis and its benefits and risks compared with other rheumatoid arthritis drugs also require further study.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M Schiff, M Keiserman, C Codding, S Songcharoen, A Berman, S Nayiager, C Saldate, T Li, R Aranda, J-C Becker, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate Ann Rheum Dis, August 1, 2008; 67(8): 1096 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H K Genant, C G Peterfy, R Westhovens, J-C Becker, R Aranda, G Vratsanos, J Teng, and J M Kremer Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial Ann Rheum Dis, August 1, 2008; 67(8): 1084 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Cole, T. Li, P. Lin, R. MacLean, and G. V. Wallenstein Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept Rheumatology, July 1, 2008; 47(7): 1044 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Isaacs Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future Rheumatology, May 25, 2008; (2008) ken163v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T Felson, B. Zhang, and J. N Siegel Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievable Ann Rheum Dis, May 1, 2008; 67(5): 580 - 583. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hamel, P. Doodes, Y. Cao, Y. Wang, J. Martinson, R. Dunn, M. R. Kehry, B. Farkas, and A. Finnegan Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4+ T Cell Reactivity J. Immunol., April 1, 2008; 180(7): 4994 - 5003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vera-Llonch, E. Massarotti, F. Wolfe, N. Shadick, R. Westhovens, O. Sofrygin, R. Maclean, Y. Yuan, and G. Oster Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate Rheumatology, April 1, 2008; 47(4): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Tran, S. G. Thacker, D. M. Louie, J. Oliver, P. T. White, J. L. Endres, A. G. Urquhart, K. C. Chung, and D. A. Fox Interactions of T Cells with Fibroblast-Like Synoviocytes: Role of the B7 Family Costimulatory Ligand B7-H3 J. Immunol., March 1, 2008; 180(5): 2989 - 2998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pincus, M. J. Bergman, Y. Yazici, P. Hines, K. Raghupathi, and R. Maclean An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures Rheumatology, March 1, 2008; 47(3): 345 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Roy, D. R. Mould, X.-F. Wang, L. Tay, R. Raymond, and M. Pfister Modeling and Simulation of Abatacept Exposure and Interleukin-6 Response in Support of Recommended Doses for Rheumatoid Arthritis J. Clin. Pharmacol., November 1, 2007; 47(11): 1408 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF]
|
|
|
|
|
|
M Schoels, T Kapral, T Stamm, J S Smolen, and D Aletaha Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study Ann Rheum Dis, August 1, 2007; 66(8): 1059 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P Bruce and E. G Boyce Update on Abatacept: A Selective Costimulation Modulator for Rheumatoid Arthritis Ann. Pharmacother., July 1, 2007; 41(7): 1153 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kuek, B. L Hazleman, and A. J K Ostor Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution Postgrad. Med. J., April 1, 2007; 83(978): 251 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wan, H. Nie, A. Liu, G. Feng, D. He, R. Xu, Q. Zhang, C. Dong, and J. Z. Zhang Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis J. Immunol., December 15, 2006; 177(12): 8844 - 8850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii2 - iii15. [Full Text] [PDF]
|
|
|
|
 |
|
 Abatacept in MTX-Resistant RA Journal Watch (General), October 3, 2006; 2006(1003): 6 - 6. [Full Text]
|
|
|
|
 |
|
 M. Boers Abatacept in rheumatoid arthritis: a new branch on the "biologics" tree. Ann Intern Med, June 20, 2006; 144(12): 933 - 935. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
